Prosecution Insights
Last updated: November 20, 2026
Application No. 16/947,921

ADJUSTING INSULIN DELIVERY RATES

Final Rejection §103
Filed
Aug 24, 2020
Priority
Jan 14, 2016 — provisional 62/278,978 +2 more
Examiner
KOO, BENJAMIN K
Art Unit
3783
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Insulet Corporation
OA Round
6 (Final)
57%
Grant Probability
Moderate
7-8
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 57% of resolved cases
57%
Career Allowance Rate
123 granted / 215 resolved
-12.8% vs TC avg
Strong +50% interview lift
Without
With
+49.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
43 currently pending
Career history
265
Total Applications
across all art units

Statute-Specific Performance

§101
2.4%
-37.6% vs TC avg
§103
47.8%
+7.8% vs TC avg
§102
14.6%
-25.4% vs TC avg
§112
31.7%
-8.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 215 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Information Disclosure Statement Due to a long list of IDS submitted, Examiner refers Applicant to MPEP 2004 and in particular to point 13 which states: It is desirable to avoid the submission of long lists of documents if it can be avoided. Eliminate clearly irrelevant and marginally pertinent cumulative information. If a long list is submitted, highlight those documents which have been specifically brought to applicant's attention and/or are known to be of most significance. See Penn Yan Boats, Inc. V. Sea Lark Boats, Inc., 359 F. Supp. 948, 175 USPQ 260 (S.D. Fla. 1972), aff'd, 479 F.2d 1338, 178 USPQ 577 (5th Cir. 1973), cert. denied, 414 U.S. 874 (1974). But cf. Molins PLC V. Textron Inc., 48 F.3d 1172, 33 USPQ2d 1823 (Fed. Cir. 1995). In the instant case, it appears that many of the cited references are either irrelevant or marginally pertinent. Note that consideration by the examiner of the information submitted in an IDS means nothing more than considering the documents in the same manner as other documents in Office search files are considered by the examiner while conducting a search of the prior art in a proper field of search. See MPEP 609. Claim Rejections - 35 USC § 103 The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. Claims 37-40 and 42 are rejected under 35 U.S.C. 103 as being unpatentable over U.S. Patent Publication No. 2014/0032196 to Albisser in view of U.S. Patent Publication No. 2015/0289823 to Rack-Gomer et al. (“Rack”). Regarding claim 37, Albisser discloses a system comprising a glucose sensor (i.e., conventional glucose meter) configured to obtain glucose data from a person with diabetes (PWD) ([0027]); an interface (80), a controller ([0025]; i.e., controller of computer 13) comprising: at least one processor (i.e., processor of computer 13) ([0025]; Fig. 1); and at least one non-transitory computer-readable storage medium (i.e., memory or program storage of computer and device 12) storing instructions thereon ([0025]-[0026]) that, when executed by the at least one processor, cause the controller to: receive, by way of the interface, a user selection of a fear of hypoglycemia index (FHI) for the PWD ([0050]-[0051]; i.e., probability of risk is selectable range), the FHI defining an acceptable probability of defining an acceptable probability that an undesirable blood glucose level of the PWD will be achieved ([0051]; i.e., probability of risk for hypoglycemic threshold); calculate an event probability that the undesirable blood glucose level of the PWD will be achieved ([0051]-[0054]; i.e., calculating probability risk of the expected blood glucose in order to determine the probability risk is greater than 5% or other selectable range); determine an insulin therapy program for the PWD to at least substantially align the calculated event probability with the acceptable probability defined by the FHI (step 105) ([0055]; Fig. 8); and generate instructions to deliver insulin according to the insulin therapy program ([0058]); and an insulin pump (i.e., insulin pump) configured to receive the generated instructions from the controller and to deliver insulin according to the generated instructions ([0058]; i.e., dosing adjusted based on suggested quantity), but does not teach the aggressiveness index. Rack teaches a selection of an aggressiveness index defining a preference of the PWD to have one of higher, lower, or moderate blood glucose levels relative to one more threshold blood glucose values ([0318], Figs. 31A-31B; for example, when the glucose level is low as shown in Figs. 31A, and the user chooses the “Nothing” option, the user is preferring to have a lower glucose level, it is noted that due to the alternative language, simultaneous teaching all three of the blood glucose levels are not required to meet the limitations of the claim). It would be obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to have incorporated the aggressiveness index of Rack into the system of Albisser in order to allow the user to option to choose to remain at a higher or lower blood glucose level depending on the urgency or the particular situation [0324-0327] and/or to minimize the number of alerts. Once combined, the FHI would be based at least partially on the selected aggressiveness index. Regarding claim 38, Albisser and Rack disclose the system of claim 37, Rack further teaching the undesirable blood glucose level comprises a blood glucose level of the PWD being below a threshold blood glucose level of the one or more threshold glucose values (Fig. 31A). Regarding claim 39, Albisser and Rack disclose the system of claim 38, Albisser further teaching calculating the event probability that the undesirable blood glucose level will be achieved comprises: receiving an up-to-date blood glucose data for the PWD from the glucose sensor (step 33) ([0035]); and calculating the event probability of the PWD achieving a blood glucose level below the threshold blood glucose level based at least partially on the up-to-date blood glucose data ([0051]). Regarding claim 40, Albisser and Rack disclose the system of claim 39, Albisser further teaching determining the insulin therapy program for the PWD to at least substantially align the event probability with the acceptable probability comprises: determining one or more target blood glucose levels aligning the event probability of the PWD achieving a blood glucose level below the threshold blood glucose level with the acceptable probability defined within the FHI (step 104) ([0054]); and calculating a basal insulin dose or rate for the PWD based at least in part on the determined one or more target blood glucose levels ([0059]). Regarding claim 42, Albisser and Rack disclose the system of claim 37, Albisser further teaching the controller comprises a device separate and discrete from the insulin pump (Fig. 1). Claim 41 is rejected under 35 U.S.C. 103 as being unpatentable over Albisser and Rack as applied to claim 37 above, and further in view of U.S. Patent Publication No. 2005/0055242 to Bello. Regarding claim 41, Albisser and Rack disclose the system of claim 37, Albisser further teaching the controller is part of a computer ([0025]) and that the system comprises an insulin pump ([0032], [0058]) but does not explicitly disclose that the insulin pump comprises the controller. However, it has been held that choosing from a finite number of solutions to obtain a predictable result is a rationale for determining obviousness. KSR International Co. V. Teleflex Inc. (KSR), 550 U.S., 82 USPQ2d 1385 (2007). It can be seen that there are only a finite number of solutions for how the controller and the insulin pump can be related: the controller is part of the insulin pump or the controller is separate and discrete from the insulin pump. Therefore, it also would have been obvious one of ordinary skill in the art to modify the system of Albisser with the insulin pump comprising the controller since this is one of a limited number of possible ways that the insulin pump and the controller are related to each other. Moreover, it is noted that Bello also discloses a system for delivering medication including insulin ([0261]), wherein the pumping unit of the infusion system may include the controller or alternatively does not have a controller ([0427]). Therefore, since both Albisser and Bello discloses a system for delivering insulin, it would have been obvious to one of ordinary skill in the art before the effective filing date of the invention to modify Albisser with the feature of the insulin pump comprising the controller since Bello discloses that it is well known in the art for a pumping unit delivering medication to not have a controller but accept control signals from a separate controller such as a central computer (similar to the configuration disclosed by Albisser) as an alternative to a pumping unit comprising the controller ([0427] of Bello). Response to Arguments Applicant’s arguments and amendments with respect to claim objections have been fully considered and are persuasive. The claims objections have been withdrawn. Applicant’s arguments and amendments with respect to the art rejections have been fully considered and are persuasive. Therefore, the rejections have been withdrawn. However, upon further consideration, a new ground of rejection is made in view of Albisser and Rack as shown above. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BENJAMIN KOO whose telephone number is (703)756-1749. The examiner can normally be reached M-F 8am-5pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Michael Tsai can be reached at (571) 270-5246. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /B.K./Examiner, Art Unit 3783 /THEODORE J STIGELL/Primary Examiner, Art Unit 3783
Read full office action

Prosecution Timeline

Show 7 earlier events
Aug 12, 2024
Response Filed
Nov 21, 2024
Final Rejection mailed — §103
Jan 21, 2025
Response after Non-Final Action
Feb 21, 2025
Request for Continued Examination
Feb 25, 2025
Response after Non-Final Action
Apr 10, 2025
Non-Final Rejection mailed — §103
Jul 10, 2025
Response Filed
Nov 03, 2026
Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12758741
CATHETER HAVING SHAFT ACCOMMODATION PORTION THAT ACCOMMODATES AND IS FUSED TO ELONGATED SHAFT
4y 1m to grant Granted Oct 13, 2026
Patent 12728206
AUTO-INJECTOR
4y 5m to grant Granted Sep 08, 2026
Patent 12714839
TECHNOLOGIES FOR NEEDLES WITH MICROCHANNELS
4y 7m to grant Granted Aug 25, 2026
Patent 12697469
IV CATHETER INSERTION GUIDE
4y 10m to grant Granted Aug 04, 2026
Patent 12685816
BILATERAL-DRIVEN PATCH-TYPE DRUG INFUSION DEVICE
3y 8m to grant Granted Jul 21, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

7-8
Expected OA Rounds
57%
Grant Probability
99%
With Interview (+49.7%)
3y 4m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 215 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month